High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives

Annals of Otology, Rhinology & Laryngology

Volumn 97, Issue 2, 1988, Pages 133-137

  Van Der Hulst, R J A M ^a   Dreschler, W A ^a   Urbanus, N A M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

audiometry; carboplatin; cisplatin; high frequencies; ototoxicity

Indexed keywords

CARBOPLATIN; CISPLATIN;

AUDIOMETRY; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; OTOTOXICITY;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; AUDIOMETRY; CARBOPLATIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEARING DISORDERS; HEARING LOSS, HIGH-FREQUENCY; HUMAN; MALE; MIDDLE AGE; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0023943188     PISSN: 00034894     EISSN: 19433572     Source Type: Journal    
DOI: 10.1177/000348948809700208     Document Type: Article

References (16)

1. Aquilar-Markulis NV Beckley S Priore R. Auditory toxicity effects of long-term cisdichlorodiamine platinum II therapy in genito-urinary cancer patients. J Surg Oncol 1981; 16: 111–23
2. Rybak LP. Cis-platinum associated hearing loss. J Laryngol Otol 1981; 95: 745–7
3. Vermorken JB Kapteyn TS Hart AAM Pinedo HM. Ototoxicity of cis-diaminedichloroplatinum II. Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53–8
4. Fausti SA Schechter MA Rappaport BZ Frey RH Mass RE. Early detection of cisplatin ototoxicity. Cancer 1984; 53: 224–31
5. Van Zeyl LPPM Conijn EAJG Rodenburg M Tange RA Brocaar MP. Analysis of hearing losses due to cis-diaminedich Joro platinum II. Arch Otorhinolaryngol 1984; 239: 255–62
6. Helson L Okonkwo E Anton L Cvitkovic E. Cis-platinum ototoxicity. Clin Toxicol 1979; 13: 469–78
7. Von Hoff DD Schilsky R Reichert CM, et al, Toxic effects of cis-dichlorodiamine platinum II in man. Cancer Treat Rep 1979; 63: 1527–31
8. Reddel RR Kefford RF Grant JM Coates AS Fox RM Tatersall MHN. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep 1982; 66: 19–23
9. Strauss M Towfighi J Lord S Lipton A Harvey HA Brown B. Cis-platinum ototoxicity: Clinical experience and temporal bone histopathology. Laryngoscope 1983; 93: 1554–9
10. Tange RA. Differences in the cochlear degeneration pattern in the guinea pig as a result of gentamicin and cis-platinum intoxication. Clin Otolaryngol 1984; 9: 323–7
11. Jacobson EJ Downs MP Fletcher JL. Clinical findings in high-frequency thresholds during known ototoxic drug usage. J Audiol Res 1969; 9: 379–85
12. Osterhammel D. High frequency audiometry. Scand Audiol 1980; 9: 249–56
13. Fausti SA Frey RH Erickson DA Rappaport BZ Cleary EJ. A system for evaluating auditory function from 8000–20,000 Hz. J Acoust Soc Am 1979; 66: 1713–8
14. Dreschler WA van der Hulst RJAM Tange RA Urbanus NAM. The role of high frequency audiometry in early detection of ototoxicity. Audiology 1985; 24: 387–95
15. Nakai Y Konishi K Chang KC. Ototoxicity of the anticancer drug cisplatinum. Acta Otolaryngol (Stockh) 1982; 93: 227–32
16. Tange RA Dreschler WA van der Hulst RJAM. The importance of high-tone audiometry in ototoxicity monitoring. Arch Otorhinolaryngol 1985; 242: 77–81